Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ITOS 
Iteos Therapeutics Inc (ITOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ITOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11
1 Year Target Price $11
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.87% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 380.82M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 6 | Beta 1.51 | 52 Weeks Range 4.80 - 18.13 | Updated Date 06/30/2025 |
52 Weeks Range 4.80 - 18.13 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -428.31% |
Management Effectiveness
Return on Assets (TTM) -14.54% | Return on Equity (TTM) -23.68% |
Valuation
Trailing PE - | Forward PE 12.56 | Enterprise Value -134109002 | Price to Sales(TTM) 10.88 |
Enterprise Value -134109002 | Price to Sales(TTM) 10.88 | ||
Enterprise Value to Revenue 1.26 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 38273800 | Shares Floating 22095845 |
Shares Outstanding 38273800 | Shares Floating 22095845 | ||
Percent Insiders 1.14 | Percent Institutions 114.61 |
Analyst Ratings
Rating 3 | Target Price 11 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Iteos Therapeutics Inc
Company Overview
History and Background
Iteos Therapeutics, Inc. is a biopharmaceutical company focused on developing novel cancer immunotherapies. Founded in 2011, it has focused on targeting the tumor microenvironment to enhance anti-tumor immune responses, progressing several molecules into clinical development.
Core Business Areas
- Therapeutic Development: Focuses on discovering and developing novel cancer immunotherapies targeting the tumor microenvironment.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates in various cancer types.
- Research and Development: Investing in research to identify new targets and develop innovative therapeutic approaches in immuno-oncology.
Leadership and Structure
The leadership team comprises executives with expertise in drug development and commercialization. The company has a structured organizational framework to support its R&D efforts.
Top Products and Market Share
Key Offerings
- EOS-448 (anti-TIGIT antibody): An IgG1 antibody designed to enhance antitumor responses through blocking TIGIT. It is currently in Phase 2/3 clinical trials in combination with other therapies. Market share is not yet established due to its developmental stage. Competitors include Gilead's domvanalimab and other anti-TIGIT antibodies.
- Inupadenant (A2aR antagonist): An adenosine A2a receptor antagonist designed to reverse adenosine-mediated immunosuppression. It is also in Phase 2 clinical development. Market share is not yet established as the drug is still in development. Competitors include Arcus Biosciences' AB928 and other A2aR antagonists.
Market Dynamics
Industry Overview
The immuno-oncology market is characterized by rapid innovation and strong demand for effective cancer therapies. The industry is highly competitive, with numerous companies developing novel immunotherapies.
Positioning
Iteos Therapeutics is positioned as an innovative company targeting the tumor microenvironment with novel immunotherapies. Its competitive advantage lies in its unique targets and combination therapy strategies.
Total Addressable Market (TAM)
The global cancer immunotherapy market is estimated to be worth hundreds of billions of dollars. Iteos Therapeutics is positioned to capture a share of this market with its innovative pipeline of novel immunotherapies.
Upturn SWOT Analysis
Strengths
- Novel drug targets
- Strong research and development capabilities
- Experienced leadership team
- Strategic collaborations with pharmaceutical companies
Weaknesses
- Dependence on clinical trial outcomes
- Limited commercial infrastructure
- High cash burn rate
- Early stage development
Opportunities
- Expanding clinical trials into new indications
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Securing regulatory approvals for its drug candidates
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- ARCI
- NKTR
- AZN
Competitive Landscape
Iteos Therapeutics competes with numerous companies in the immuno-oncology space. Its advantages include novel drug targets and combination therapy strategies, while its disadvantages include its smaller size and limited resources compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its drug candidates through clinical trials and partnerships.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include expanding clinical trials for EOS-448 and inupadenant, securing collaborations with pharmaceutical companies, and presenting data at scientific conferences.
Summary
Iteos Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of immuno-oncology candidates. Its strengths lie in its novel targets and strategic partnerships. However, it faces risks associated with clinical trial outcomes and competition from larger companies. Future success hinges on the successful development and commercialization of its drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Iteos Therapeutics' website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iteos Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-07-24 | President, CEO & Director Dr. Michel Detheux Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 173 | |
Full time employees 173 | |||
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.